Daten aus praktischer Anwendung bestätigen hohe Wirksamkeit des Pfizer-BioNTech COVID-19-Impfstoffs und die große Bedeutung von Impfungen für die öffentliche Gesundheit ein Jahr nach offiziellem Beginn der Pandemie
11 mars 2021 06h45 HE
|
BioNTech SE
Vom israelischen Gesundheitsministeriums (Ministry of Health, MoH) gesammelte Daten aus der praktischen Anwendung zeigen signifikant verringerte COVID-19-Inzidenzrate in Personen, die beide Dosen des...
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
11 mars 2021 06h45 HE
|
BioNTech SE
Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health Data...
Appointment of Ben Vertannes as Head of Global Marketing
08 mars 2021 02h00 HE
|
Ascension
PRESS RELEASE Appointment of Ben Vertannes as Head of Global Marketing LONDON, March 8, 2021 – Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage pharmaceutical company...
Pregnant Patients Should Weigh Risk of COVID Jab, States Association of American Physicians and Surgeons (AAPS)
04 mars 2021 13h39 HE
|
Association of American Physicians and Surgeons
TUCSON, Ariz., March 04, 2021 (GLOBE NEWSWIRE) -- The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) have recommended that COVID-19...
Pfizer und BioNTech beginnen Studie mit COVID-19-Auffrischungsimpfung und neuen Impfstoffvarianten als Teil eines umfassenden Entwicklungsplans
25 févr. 2021 06h45 HE
|
BioNTech SE
Die Verabreichung einer dritten Dosis des Pfizer-BioNTech COVID-19-Impfstoffs BNT162b2 wird als Teil der Phase-1/2/3-Studie untersucht; die Teilnehmer der Phase-1-Studie erhalten eine 30µg-Dosis...
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
25 févr. 2021 06h45 HE
|
BioNTech SE
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the...
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMI
24 févr. 2021 10h35 HE
|
PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR...
Global Schizophrenia Drug Market is estimated to be US$ 9.8 Bn by 2030 with a CAGR of 2.7% during the forecast period - by PMI
24 févr. 2021 10h05 HE
|
PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The global schizophrenia drug market accounted for US$ 7.5 Bn in 2020 and is estimated to be US$ 9.8 Bn by 2030 and is anticipated to register a CAGR of...
Pfizer und BioNTech reichen Stabilitätsdaten zur Lagerung des COVID-19-Impfstoffs bei Standard-Gefriertemperaturen bei der U.S.-amerikanischen FDA ein
19 févr. 2021 07h07 HE
|
BioNTech SE
Vorgeschlagenes Etiketten-Update in den USA würde die Lagerung des Impfstoffs für zwei Wochen bei -25°C bis -15°C (-13°F bis 5°F) ermöglichenFalls genehmigt, könnte die neue Lagerungsmöglichkeit...
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
19 févr. 2021 07h07 HE
|
BioNTech SE
Proposed U.S. EUA label update would enable the vaccine to be stored at -25°C to -15°C (-13°F to 5°F) for a total of two weeks If approved, new storage option could offer pharmacies and vaccination...